Luminescent-activated transfected killer cells to monitor leukocyte trafficking during systemic bacterial and fungal infection

Journal of Infectious Diseases

Volumn 205, Issue 2, 2012, Pages 337-347

  Lin, Lin ^a,b   Ibrahim, Ashraf S ^b,c   Baquir, Beverlie ^a   Palosaari, Andrew ^a   Spellberg, Brad ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIBODY; MESSENGER RNA;

ACINETOBACTER INFECTION; ACTIVATED TRANSFECTED KILLER CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BIOACCUMULATION; CANDIDIASIS; CELL MIGRATION; CELL SPREADING; CELL SURVIVAL; CELL THERAPY; CONTROLLED STUDY; IMMUNOGENICITY; IN VIVO STUDY; KIDNEY; KILLER CELL; LEUKOCYTE MIGRATION; LUMINESCENCE; LUNG; MALE; MESENTERY; MOUSE; MYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RNA TRANSCRIPTION; SPLEEN; STAPHYLOCOCCUS INFECTION; THERAPY EFFECT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CYCLOPHOSPHAMIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HL-60 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY; KILLER CELLS, NATURAL; LUMINESCENCE; LUNG; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; NEUTROPENIA; PULMONARY ASPERGILLOSIS; RNA, MESSENGER; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THYMIDINE KINASE; TIME FACTORS; TRANSFECTION;

EID: 84555178386     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir725     Document Type: Article

References (27)

1. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 105:478-83. (Pubitemid 29013332)
2. Nucci M, Pulcheri W, Spector N, et al. Fungal infections in neutropenic patients. A 8-year prospective study. Rev Inst Med Trop Sao Paulo 1995; 37:397-406. (Pubitemid 26027660)
3. Lehrnbecher T, Groll AH, Chanock SJ. Treatment of fungal infections in neutropenic children. Curr Opin Ped 1999; 11:47-55. (Pubitemid 29090071)
4. Hubel K, Dale DC, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 2001; 183:321-8. (Pubitemid 32066035)
5. Alavi JB, Root RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Eng J Med 1977; 296:706-11. (Pubitemid 8066532)
6. Herzig RH, Herzig GP, Graw RG Jr, Bull MI, Ray KK. Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Eng J Med 1977; 296:701-5. (Pubitemid 8066531)
7. Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies. XI. Blood granulocyte kinetics in polycythemia vera, infection, and myelofibrosis. J Clin Invest 1965; 44:778-88.
8. Marsh JC, Boggs DR, Cartwright GE,WintrobeMM. Neutrophil kinetics in acute infection. J Clin Invest 1967; 46:1943-53.
9. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. Neutrophil kinetics in man. J Clin Invest 1976; 58:705-15.
10. Huestis DW, Glasser L. The neutrophil in transfusion medicine. Transfusion 1994; 34:630-46. (Pubitemid 24246144)
11. Glasser L. Effect of storage on normal neutrophils collected by discontinuous-flow centrifugation leukapheresis. Blood 1977; 50: 1145-50. (Pubitemid 8245217)
12. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective casecontrol analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101:2859-65. (Pubitemid 39603195)
13. Spellberg BJ, Collins M, French SW, Edwards JE Jr, Fu Y, Ibrahim AS. A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol 2005; 78:338-44. (Pubitemid 41061306)
14. Spellberg BJ, Collins M, Avanesian V, et al. Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. J Leukoc Biol 2006; 81:632-41. (Pubitemid 46393541)
15. Lin L, Ibrahim AS, Baquir B, et al. Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. J Infect Dis 2010; 201:1708-17.
16. Spellberg BJ, Johnston D, Phan QT, et al. Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun 2003; 71:5756-64. (Pubitemid 37205629)
17. Spellberg B, Ibrahim AS, Yeaman M, et al. The anti-fungal rAls3p-N vaccine protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008; 76:4574-80.
18. Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703.
19. Van t Wout JW, Mattie H, van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Ch 1989; 33:147-51. (Pubitemid 19053848)
20. Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE Jr, Ibrahim AS. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Ch 2004; 48:1908-11. (Pubitemid 38544412)
21. Rieg G, Spellberg B, Schwartz J, et al. Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis. Antimicrob Agents Ch 2006; 50:2895-6. (Pubitemid 44198726)
22. Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B. Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Mic 2009; 55:293-5.
23. Spellberg B, IbrahimAS, Edwards JE Jr, Filler SG.Micewith disseminated candidiasis die of progressive sepsis. J Infect Dis 2005; 192:336-43. (Pubitemid 40993405)
24. Spellberg BJ, Ibrahim AS, Avenissian V, et al. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 2005; 73:6191-3. (Pubitemid 41193065)
25. van Deventer AJ, Goessens WH, van Belkum A, van Etten EW, van Vliet HJ, Verbrugh HA. PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice. J Clin Microbiol 1996; 34:25-8. (Pubitemid 126506885)
26. Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KM. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemoth 2009; 63:763-6.
27. Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. J Antimicrob Chemoth 2010; 65:725-8.